Clinical and Parasite Species Risk Factors for Pentavalent Antimonial Treatment Failure in Cutaneous Leishmaniasis in Peru | Zendy

Alejandro LlanosCuentas | Zendy; Gianfranco Tulliano | Zendy; Roger V. AraujoCastillo | Zendy; César MirandaVerástegui | Zendy; G. Santamaria-Castrellon | Zendy; Luis Ramirez | Zendy; M. Lazo | Zendy; Simonne De Doncker | Zendy; Marleen Boelaert | Zendy; Jo Robays | Zendy; JeanClaude Dujardin | Zendy; Jorge Arévalo | Zendy; François Chappuis | Zendy

Open Access

Clinical and Parasite Species Risk Factors for Pentavalent Antimonial Treatment Failure in Cutaneous Leishmaniasis in Peru

Author(s) -

Alejandro LlanosCuentas,

Gianfranco Tulliano,

Roger V. AraujoCastillo,

César MirandaVerástegui,

G. Santamaria-Castrellon,

Luis Ramirez,

M. Lazo,

Simonne De Doncker,

Marleen Boelaert,

Jo Robays,

JeanClaude Dujardin,

Jorge Arévalo,

François Chappuis

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/524042

Subject(s) - medicine , leishmaniasis , cutaneous leishmaniasis , dermatology , parasite hosting , immunology , computer science , world wide web

Treatment for cutaneous leishmaniasis (CL) with standard pentavalent antimonial therapy is hampered by cumbersome administration, toxicity, and potential failure. Knowledge of factors influencing treatment outcome is essential for successful management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research